Rituxan looks to become new front-line option in chronic lymphocytic leukaemia
This article was originally published in Scrip
Executive Summary
Genentech/Roche/Biogen Idec's Rituxan/MabThera (rituximab) has delayed disease progression in chronic lymphocytic leukaemia (CLL) by about 10 months in two Phase III trials whose data were recently presented at the American Society of Hematology (ASH) meeting in San Francisco.